Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
AstraZeneca
Express Scripts
Moodys
Baxter

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Patritumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Patritumab?

Patritumab is an investigational drug.

There have been 5 clinical trials for Patritumab. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Head and Neck Neoplasms, Carcinoma, Squamous Cell, and Neoplasms by Site. The leading clinical trial sponsors are Daiichi Sankyo Inc., QuantumLeap Healthcare Collaborative, and Covance.

There are six US patents protecting this investigational drug and one hundred and sixty-seven international patents.

Recent Clinical Trials for Patritumab
TitleSponsorPhase
A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and NeckCovancePhase 2
A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and NeckDaiichi Sankyo Inc.Phase 2
A Study Using Patritumab in Combination With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck CancerDaiichi Sankyo Inc.Phase 1

See all Patritumab clinical trials

Clinical Trial Summary for Patritumab

Top disease conditions for Patritumab
Top clinical trial sponsors for Patritumab

See all Patritumab clinical trials

US Patents for Patritumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Patritumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Patritumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Patritumab   Start Trial P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)   Start Trial
Patritumab   Start Trial Fragments of p97 and uses thereof biOasis Technologies, Inc. (Richmond, CA)   Start Trial
Patritumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Patritumab   Start Trial Anti-CD324 monoclonal antibodies and uses thereof ABBVIE STEMCENTRX LLC (North Chicago, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Patritumab

Drugname Country Document Number Estimated Expiration Related US Patent
Patritumab Canada 2900764 2033-02-08   Start Trial
Patritumab European Patent Office 2954056 2033-02-08   Start Trial
Patritumab Hong Kong 1218930 2033-02-08   Start Trial
Patritumab Japan 2016509014 2033-02-08   Start Trial
Patritumab World Intellectual Property Organization (WIPO) 2014124326 2033-02-08   Start Trial
Patritumab Australia 2013220749 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Johnson and Johnson
McKinsey
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.